FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115367908> ?p ?o ?g. }

• W3115367908 endingPage "1262" @default.
• W3115367908 startingPage "1245" @default.
• W3115367908 abstract "Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is an oncolytic immunotherapy approved in Europe for the treatment of unresectable metastatic melanoma (stage IIIB–IVM1a). This study characterised real-world use of T-VEC in four European countries. Data on demographics, treatment pattern, safety, and clinical effectiveness were examined in a retrospective chart review of patients with stage IIIB–IVM1a unresectable melanoma treated with T-VEC in surgical (the Netherlands) and medical (Austria, Germany, UK) oncology settings. Overall, 66 patients were included (the Netherlands: n = 31; Austria, Germany, UK: n = 35). The median age was 69 years and 59.1% were female. At the time of T-VEC initiation, 47 patients (71.2%) had stage IIIB/C disease; of these, 30 were from the Netherlands. Although 72.7% patients overall received T-VEC as first-line therapy, this was higher in the Netherlands than the other countries (93.5% vs 54.3%). Of the 47 patients who discontinued T-VEC, 26 (55.3%) had no remaining injectable lesions (potentially indicating complete response); 20/26 of these patients were from the Netherlands. One patient discontinued T-VEC due to toxicity. This study is the first comprehensive multinational evaluation of the use of T-VEC to treat unresectable stage IIIB/C–IVM1a melanoma in real-world clinical practice in Europe. The differences between European countries were apparent, with physicians in the Netherlands using T-VEC in patients with earlier advanced disease stage and in the first-line setting compared with other countries." @default.
• W3115367908 created "2021-01-05" @default.
• W3115367908 creator A5002605575 @default.
• W3115367908 creator A5007525817 @default.
• W3115367908 creator A5012068119 @default.
• W3115367908 creator A5012738162 @default.
• W3115367908 creator A5013066121 @default.
• W3115367908 creator A5019573174 @default.
• W3115367908 creator A5025256131 @default.
• W3115367908 creator A5038986027 @default.
• W3115367908 creator A5042724544 @default.
• W3115367908 creator A5046096521 @default.
• W3115367908 creator A5077331259 @default.
• W3115367908 creator A5087532834 @default.
• W3115367908 creator A5091348562 @default.
• W3115367908 date "2020-12-26" @default.
• W3115367908 modified "2023-10-18" @default.
• W3115367908 title "A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries" @default.
• W3115367908 cites W1995029154 @default.
• W3115367908 cites W2086591619 @default.
• W3115367908 cites W2099648846 @default.
• W3115367908 cites W2109274792 @default.
• W3115367908 cites W2120729896 @default.
• W3115367908 cites W2473956396 @default.
• W3115367908 cites W2555619826 @default.
• W3115367908 cites W2736194991 @default.
• W3115367908 cites W2750781282 @default.
• W3115367908 cites W2763265527 @default.
• W3115367908 cites W2897056135 @default.
• W3115367908 cites W2898003394 @default.
• W3115367908 cites W2904494044 @default.
• W3115367908 cites W2913700843 @default.
• W3115367908 cites W2914448678 @default.
• W3115367908 cites W2954618642 @default.
• W3115367908 cites W2955927679 @default.
• W3115367908 cites W2967262233 @default.
• W3115367908 cites W2977296766 @default.
• W3115367908 cites W4255398094 @default.
• W3115367908 doi "https://doi.org/10.1007/s12325-020-01590-w" @default.
• W3115367908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7889564" @default.
• W3115367908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33368016" @default.
• W3115367908 hasPublicationYear "2020" @default.
• W3115367908 type Work @default.
• W3115367908 sameAs 3115367908 @default.
• W3115367908 citedByCount "11" @default.
• W3115367908 countsByYear W31153679082021 @default.
• W3115367908 countsByYear W31153679082022 @default.
• W3115367908 countsByYear W31153679082023 @default.
• W3115367908 crossrefType "journal-article" @default.
• W3115367908 hasAuthorship W3115367908A5002605575 @default.
• W3115367908 hasAuthorship W3115367908A5007525817 @default.
• W3115367908 hasAuthorship W3115367908A5012068119 @default.
• W3115367908 hasAuthorship W3115367908A5012738162 @default.
• W3115367908 hasAuthorship W3115367908A5013066121 @default.
• W3115367908 hasAuthorship W3115367908A5019573174 @default.
• W3115367908 hasAuthorship W3115367908A5025256131 @default.
• W3115367908 hasAuthorship W3115367908A5038986027 @default.
• W3115367908 hasAuthorship W3115367908A5042724544 @default.
• W3115367908 hasAuthorship W3115367908A5046096521 @default.
• W3115367908 hasAuthorship W3115367908A5077331259 @default.
• W3115367908 hasAuthorship W3115367908A5087532834 @default.
• W3115367908 hasAuthorship W3115367908A5091348562 @default.
• W3115367908 hasBestOaLocation W31153679081 @default.
• W3115367908 hasConcept C121608353 @default.
• W3115367908 hasConcept C126322002 @default.
• W3115367908 hasConcept C141071460 @default.
• W3115367908 hasConcept C143998085 @default.
• W3115367908 hasConcept C146357865 @default.
• W3115367908 hasConcept C151730666 @default.
• W3115367908 hasConcept C2777658100 @default.
• W3115367908 hasConcept C2777701055 @default.
• W3115367908 hasConcept C2781433595 @default.
• W3115367908 hasConcept C502942594 @default.
• W3115367908 hasConcept C71924100 @default.
• W3115367908 hasConcept C86803240 @default.
• W3115367908 hasConceptScore W3115367908C121608353 @default.
• W3115367908 hasConceptScore W3115367908C126322002 @default.
• W3115367908 hasConceptScore W3115367908C141071460 @default.
• W3115367908 hasConceptScore W3115367908C143998085 @default.
• W3115367908 hasConceptScore W3115367908C146357865 @default.
• W3115367908 hasConceptScore W3115367908C151730666 @default.
• W3115367908 hasConceptScore W3115367908C2777658100 @default.
• W3115367908 hasConceptScore W3115367908C2777701055 @default.
• W3115367908 hasConceptScore W3115367908C2781433595 @default.
• W3115367908 hasConceptScore W3115367908C502942594 @default.
• W3115367908 hasConceptScore W3115367908C71924100 @default.
• W3115367908 hasConceptScore W3115367908C86803240 @default.
• W3115367908 hasIssue "2" @default.
• W3115367908 hasLocation W31153679081 @default.
• W3115367908 hasLocation W31153679082 @default.
• W3115367908 hasOpenAccess W3115367908 @default.
• W3115367908 hasPrimaryLocation W31153679081 @default.
• W3115367908 hasRelatedWork W2003938723 @default.
• W3115367908 hasRelatedWork W2047967234 @default.
• W3115367908 hasRelatedWork W2118496982 @default.
• W3115367908 hasRelatedWork W2364998975 @default.
• W3115367908 hasRelatedWork W2369162477 @default.
• W3115367908 hasRelatedWork W2439875401 @default.

• next